default author photo

Michael Thomas Mark

Kantonsspital Graubünden

SCHOLARLY PAPERS

3

DOWNLOADS

101

TOTAL CITATIONS

0

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

First-Line Durvalumab in Patients with Pd-L1 Positive, Advanced Non-Small Cell Lung Cancer (Nsclc) with a Performance Status of 2 (Ps2). Primary Analysis of the Multicenter, Single-Arm Phase Ii Trial Sakk 19/17

Number of pages: 20 Posted: 27 Sep 2023
Michael Thomas Mark, Patrizia Froesch, Katrin Gysel, Sacha I. Rothschild, Alfredo Addeo, Christoph Ackermann, Sabrina Chiquet, Martina Schneider, Karin Ribi, Angela Fischer, Sara Bastian, Roger Von Moos, Markus Joerger and Martin Früh
Kantonsspital Graubünden, Oncology Institute of Southern Switzerland, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, University of Basel - University Hospital Basel, University of Geneva - Department of Oncology, Spital Thun, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Kantonsspital Graubünden, Kantonsspital Graubünden, Kantonsspital Graubünden, Cantonal Hospital of St. Gallen and Cantonal Hospital of St. Gallen
Downloads 38 (1,222,651)

Abstract:

Loading...

immunotherapy, first-line, metastatic non-small cell lung cancer, performance status 2

2.

Are Bone Targeted Agents Still Useful in Times of Immunotherapy? The Sakk 80/19 Bta Study

Number of pages: 13 Posted: 03 May 2024
Michael Thomas Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch and Roger Von Moos
Kantonsspital Graubünden, affiliation not provided to SSRN, affiliation not provided to SSRN, Oncology Institute of Southern Switzerland, affiliation not provided to SSRN, affiliation not provided to SSRN, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, affiliation not provided to SSRN, affiliation not provided to SSRN and Kantonsspital Graubünden
Downloads 37 (1,222,651)

Abstract:

Loading...

bone metastases, Bone-targeting agents, Skeletal-related events, Symptomatic skeletal events, Immunotherapy

3.

First-line immunotherapy +/- chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small Cell Lung Cancer (NSCLC) with asymptomatic brain metastases

Number of pages: 26 Posted: 19 Sep 2025
Lorenz Frehner, Sämi Schär, Stefanie Hayoz, Verena Petermichl, Philip Speicher, Sacha I. Rothschild, Laetitia A. Mauti, David König, Tobias Finazzi, Patrizia Froesch, Sabrina Marini, Anna Allemann, Michael Thomas Mark, Wolf-Dieter Janthur, Antonia Stamatiou, Yannis Metaxas, Ekin Ermis, Franca Wagner, Martin Früh and Sabine Schmid
affiliation not provided to SSRN, affiliation not provided to SSRN, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Kantonsspital St Gallen, affiliation not provided to SSRN, University of Basel - University Hospital Basel, Cantonal Hospital Winterthur, University of Basel - University Hospital Basel, affiliation not provided to SSRN, Oncology Institute of Southern Switzerland, Oncology Institute of Southern Switzerland, affiliation not provided to SSRN, Kantonsspital Graubünden, Department of Oncology/Haematology, Cantonal Hospital Aarau, Lausanne University Hospital, affiliation not provided to SSRN, Varian Medical Systems, affiliation not provided to SSRN, Universitäres Lehrund Forschungsspital and affiliation not provided to SSRN
Downloads 26 (1,372,601)

Abstract:

Loading...

NSCLC, brain metastases, immune checkpoint inhibitors, stereotactic radiotherapy